- Home
- CMPS vs PVLA Comparison
CMPS vs PVLA Comparison
Compare CMPS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | PVLA |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CMPS | PVLA |
|---|---|---|
| Price | $14.95 | $154.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $25.38 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 2.4M | 159.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104,350.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $4.88 | $56.55 |
| 52 Week High | $15.87 | $161.38 |
Technical Indicators
Market Signals| Indicator | CMPS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 53.49 |
| Support Level | $12.95 | $145.91 |
| Resistance Level | $15.87 | $159.64 |
| Average True Range (ATR) | 0.83 | 5.29 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 71.86 | 59.65 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.